These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 34187202)

  • 21. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
    Wu JJ; Pelletier C; Ung B; Tian M
    Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
    [No Abstract]   [Full Text] [Related]  

  • 24. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis.
    Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
    Clinicoecon Outcomes Res; 2020; 12():369-377. PubMed ID: 32765022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.
    Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
    J Comp Eff Res; 2021 Aug; 10(12):989-998. PubMed ID: 34187202
    [No Abstract]   [Full Text] [Related]  

  • 27. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apremilast and its role in psoriatic arthritis.
    Sandhu VK; Eder L; Yeung J
    G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence.
    Sideris E; Corbett M; Palmer S; Woolacott N; Bojke L
    Pharmacoeconomics; 2016 Nov; 34(11):1101-1110. PubMed ID: 27272887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apremilast Uses and Relevance to the Military.
    Hathaway NE; Lyford WH
    Cutis; 2021 Apr; 107(4):216-220. PubMed ID: 34096849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A meta-analysis of apremilast on psoriatic arthritis long-term assessment of clinical efficacy (PALACE).
    Qu X; Zhang S; Tao L; Song Y
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):799-805. PubMed ID: 26918950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apremilast in psoriatic arthritis.
    Schett G
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
    Garcovich S; Giovanardi G; Malvaso D; De Simone C; Peris K
    Medicine (Baltimore); 2020 Jan; 99(5):e18991. PubMed ID: 32000436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New treatment paradigms in psoriatic arthritis: an update on new therapeutics approved by the U.S. Food and Drug Administration.
    Felquer ML; Soriano ER
    Curr Opin Rheumatol; 2015 Mar; 27(2):99-106. PubMed ID: 25633241
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.